Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02781584 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG: SEL
DRUG: FIR
DRUG: CILO
DRUG: FENO
DRUG: VAS

Sponsor

Gilead Sciences